SCHEMBL1020064

SCHEMBL1020064

CCC(C)NC(=O)c1cccc(CN2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.47
HTT P42858 1/20 0.47
GLS O94925 2/20 0.46
GPR119 Q8TDV5 2/20 0.45
HDAC1 Q13547 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TBK1 Q9UHD2 1/20 0.42
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
ADRA1D P25100 1/20 0.42
HTR1B P28222 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
DRD3 P35462 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020065 1.00 PKM (0.47) PKMHTTGLSGPR119HDAC1
SCHEMBL1021644 0.85 PKM (0.56) PKMHTTHDAC1KDM4EALDH1A1
SCHEMBL8294657 0.85 GLS (0.50) PKMGLSHDAC1KDM4EALDH1A1
SCHEMBL1022120 0.84 GLS (0.49) PKMGLSHDAC1KDM4EALDH1A1
SCHEMBL4836517 0.84 CYP2D6 (0.60) GLSGPR119KDM4EALDH1A1
SCHEMBL30525131 0.82 MEN1 (0.53) GLSHDAC1KDM4EALDH1A1TBK1
SCHEMBL1020384 0.82 MEN1 (0.53) GLSHDAC1KDM4EALDH1A1TBK1
SCHEMBL8616309 0.82 GLS (0.50) HTTGLSGPR119KDM4EALDH1A1
SCHEMBL23497069 0.81 ABCB1 (0.46) PKMHTTKDM4EALDH1A1
SCHEMBL12954829 0.81 GLS (0.47) GLSTBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314091-B2 N-benzyl,N'-arylcarbonylpiperazine derivatives MSD OSS B.V. (NL) 2012-11-20 US disclosed
EP-2190827-B1 N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS ORGANON NV (NL) 2011-01-12 EP disclosed
EP-2190827-A1 N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS N.V. Organon (NL) 2010-06-02 EP disclosed
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES N.V. ORGANON AND PHARMACOPEIA, INC. 2009-10-22 US disclosed
WO-2009024550-A1 N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS N.V. ORGANON (NL) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES NPC1L1, NPC1, ABCB11 PKM 2863/4885HTT 2073/4885GLS 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.